What Are Peptides for Weight Loss? The UK Guide

If you've been looking into weight loss options recently, you've probably come across the word "peptides." Some are licensed medicines that have transformed how obesity is treated. Others are unlicensed compounds sold on the grey market - and the gap between those two categories is significant in terms of safety, legality, and effectiveness.

This guide explains what peptides are, how they support weight loss, which treatments are currently available in the UK, and what you need to know before considering any of them. It also covers the risks of unregulated peptide products being marketed online, and what genuinely supports weight management alongside licensed treatment.

What Is a Peptide?

A peptide is a short chain of amino acids, the building blocks that make up proteins. Peptides are naturally produced throughout the body and act as signalling molecules, telling cells and organs to perform specific functions. For example; hormones, enzymes, and neurotransmitters are all either peptides or proteins.

The reason peptides have attracted so much interest in weight loss is that the body already uses them to regulate appetite, blood sugar, and metabolism. Scientific research has identified which naturally occurring peptides control these processes and found ways to replicate or amplify their effects through medication.

How Do Peptides Support Weight Loss?

Not all peptides support weight loss, and those that do work in different ways. The most clinically relevant for weight loss are synthetic peptides that mimic naturally occurring gut hormones - specifically GLP-1 and GIP - which the body releases after eating.

The most important of these are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). They work through overlapping but distinct mechanisms.

GLP-1 is the better understood of the two for weight loss. It slows the rate at which food leaves your stomach, signals to the brain that you've eaten, and reduces cravings and the reward response to food. Together, these effects make it significantly easier to eat less without the persistent hunger that makes most diets hard to sustain.

GIP's primary role is as an incretin hormone. It stimulates insulin release in response to food, helping to regulate blood sugar after meals. Its contribution to weight loss is less straightforward than GLP-1's and is still an active area of research, but targeting both receptors simultaneously appears to produce greater weight reduction than GLP-1 alone, which is the basis for tirzepatide's dual mechanism.

These effects don't burn fat directly: they make it easier to eat less, leading to a lower calorie intake. They can also help reduce "food noise" - the persistent thoughts about hunger and eating that can make dieting a challenge for many people.

Clinical trials have shown that medication that mimick the action of GLP-1, also called GLP-1 receptor agonists, can produce meaningful weight loss when combined with diet and lifestyle changes. The landmark STEP 1 trial, published in the New England Journal of Medicine in 2021, found that adults using semaglutide 2.4mg weekly alongside lifestyle support lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group.¹

Which Peptides Are Available for Weight Loss in the UK?

In the UK, three peptide-based medicines are currently licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for weight management in adults.

Semaglutide (Wegovy)

Wegovy contains semaglutide, a GLP-1 receptor agonist administered as a weekly subcutaneous injection. It's licensed for adults with a BMI of 30 or above, or from 27 with at least one weight-related health condition such as high blood pressure or type 2 diabetes.² Semaglutide is also available as Ozempic, a lower-dose version licensed for type 2 diabetes. Ozempic is not licensed for weight management and should not be substituted for Wegovy.

Tirzepatide (Mounjaro)

Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist. By targeting both incretin hormones simultaneously, it tends to produce greater weight reduction than GLP-1 alone. The SURMOUNT-1 trial found that tirzepatide at its highest dose produced an average weight reduction of 20.9% over 72 weeks.³ Like Wegovy, it's a weekly injection and requires a clinical consultation to access.

Liraglutide (Saxenda)

Saxenda was the first GLP-1 receptor agonist licensed for weight management in the UK. It's a daily injection and has largely been superseded by the effectiveness and convenience of weekly options, though it remains an MHRA-licensed treatment.

What Unlicensed Peptides Are Being Marketed for Weight Loss?

Alongside these licensed medicines, a range of unlicensed peptide compounds are being sold online - often at lower prices and without the need for a prescription. These are not licensed by the MHRA and have not been through the approval process that establishes a medicine's safety, quality, and effectiveness.

These products carry significant legal and health risks and should never be purchased or taken. The MHRA has issued warnings about unlicensed injectable medicines sold online for weight loss and has taken action against suppliers.

Some of the peptide compounds being marketed for weight loss include:

• Unlicensed semaglutide - Sold by some online suppliers as a "research peptide" or "research chemical" often in powder form for self-reconstitution. These products are not manufactured to pharmaceutical standards, have no quality control, and are not legally authorised for human use in the UK.
• BPC-157 (Body Protective Compound-157) - A synthetic peptide derived from a protein found in stomach acid, widely marketed for healing and fat loss. It has no human clinical trial evidence supporting its use for weight loss and is not licensed anywhere in the world as a medicine for human use.⁴
• CJC-1295 and Ipamorelin - Growth hormone-releasing peptides (GHRPs) often sold together, with claims around increased growth hormone and fat loss. Evidence is limited to animal studies and small non-peer-reviewed reports. Neither is licensed for human use in the UK.
• Retatrutide - A triple receptor agonist (GLP-1, GIP, and glucagon) currently in late-stage clinical trials. As of 2026 it has not received MHRA or European Medicines Agency (EMA) approval, but is already being marketed online without legal authorisation.
• AOD-9604 - A synthetic fragment of human growth hormone studied for fat metabolism. Early human trials showed limited efficacy for weight loss and it has not achieved licensed status anywhere for this use.⁵

Why Are Unlicensed Peptides Dangerous?

The risks of unregulated peptide products go beyond the lack of clinical evidence. There are several specific concerns:

• Unknown long-term effects - Licensed medicines undergo years of trials and post-market surveillance. Compounds such as BPC-157 and CJC-1295 have no long-term human safety data at all.
• No manufacturing standards - Licensed medicines are produced under strict Good Manufacturing Practice (GMP) conditions with independent testing for purity, sterility, and dose accuracy. Grey market peptide products have no such oversight. Studies testing unlicensed injectable products have found contamination, incorrect dosing, and impurities including bacterial endotoxins.
• No dose guidance - Licensed treatments are started at low doses and increased gradually under clinical supervision. Unlicensed products carry no clinically validated dosing instructions, making dangerous over- or under-dosing likely.
• Infection risk from self-injection - Injecting any substance carries infection risk. This risk is substantially higher when the product itself may not be sterile.
• Drug interactions - GLP-1 receptor agonists slow gastric emptying, which affects how other medications are absorbed. Without prescriber involvement, these interactions can't be managed safely - particularly for medicines with narrow therapeutic windows, such as anticoagulants.
• Cardiovascular risk - Some peptide compounds, particularly growth hormone secretagogues, may affect insulin resistance or cardiovascular function in ways that are not adequately understood in humans.

Side Effects of Licensed Peptides for Weight Loss

Even with licensed treatments, side effects are common, particularly during the dose escalation period. The most frequently reported are gastrointestinal:

• Nausea - very common (affects more than 1 in 10 people), typically most pronounced after dose increases
• Vomiting
• Diarrhoea or constipation
• Abdominal discomfort or bloating

These effects typically reduce over time as the body adjusts to the medication. Most clinical guidance recommends starting at the lowest dose and increasing slowly to reduce their severity.

Less common but more serious side effects include pancreatitis (inflammation of the pancreas) and gallbladder disease. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should not use semaglutide or tirzepatide, based on animal study data.²

What Actually Works Alongside Licensed Peptide Treatment for Weight Loss?

Licensed GLP-1 medications are a tool, not a complete solution. The trials that produced the largest weight reductions all combined medication with structured lifestyle support. Here's what the evidence supports:

• Protein-forward diet - GLP-1 medications reduce appetite, but they don't change what you eat - only how much. Prioritising protein at each meal helps preserve muscle mass during weight loss and promotes satiety.
• Resistance exercise - A significant concern with rapid weight loss on GLP-1 medication is lean muscle loss alongside fat. Resistance training helps preserve muscle mass and supports metabolic health throughout and after treatment.
• Adequate hydration - Reduced appetite can lead to reduced fluid intake. Staying well hydrated supports digestion and helps manage nausea, which is one of the most common side effects of GLP-1 treatment.

Eating less also means taking in fewer micronutrients. Nutritional support through supplements can help maintain overall health during a caloric deficit:

• Complete multivitamin - A daily multivitamin provides a nutritional safety net when food intake is significantly reduced, covering vitamins A, C, D, the B complex, zinc, and selenium.
• Omega-3 fatty acids - EPA and DHA contribute to the maintenance of normal heart function and normal brain function and have well-studied anti-inflammatory properties relevant to the metabolic changes that accompany significant weight loss.⁶ OneVit Omega-3 provides 330mg EPA and 220mg DHA per capsule sourced from fish oil.
• Vitamin B12 - Particularly relevant for people following plant-based diets and those taking metformin alongside GLP-1 medication for type 2 diabetes, as both factors reduce B12 absorption. Look for a supplement like OneVit Vitamin B12 that contains methylcobalamin, an activated form of B12 that the body can use directly.
• Vitamin D - Vitamin D deficiency is more common in people with obesity, partly because fat tissue sequesters vitamin D and reduces its bioavailability.⁷ Supplementation is advisable for most adults in the UK, and is especially relevant during active weight loss. Pairing D3 with K2, as in OneVit's D3 and K2 formula, helps direct calcium to bones rather than soft tissue.

These supplements don't accelerate fat loss on their own, but they support the conditions for sustainable, healthy weight management and reduce the risk of nutritional deficiency during a caloric deficit.

When to Seek Further Advice

Contact your GP or prescribing clinician if you:

• Experience severe or persistent nausea, vomiting, or abdominal pain
• Develop symptoms consistent with pancreatitis: severe upper abdominal pain radiating to the back, particularly after eating
• Notice signs of hypoglycaemia (shakiness, sweating, confusion) if you're also taking insulin or sulfonylureas
• Are concerned about rapid muscle loss or persistent fatigue during treatment
• Have purchased or used unlicensed peptide products and are experiencing adverse effects - seek medical advice without delay

A full list of known side effects and drug interactions is available in the patient information leaflet supplied with your medication.

This article is intended for informational purposes only and does not replace professional medical advice. Always read the patient information leaflet supplied with your medication and speak to a healthcare professional if you have specific concerns.

References

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989--1002. doi:10.1056/NEJMoa2032183
2. Novo Nordisk Ltd. Wegovy (semaglutide) 2.4mg Summary of Product Characteristics. Electronic Medicines Compendium (eMC). Reviewed 2023. medicines.org.uk/emc
3. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205--216. doi:10.1056/NEJMoa2206038
4. Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Current Pharmaceutical Design. 2011;17(16):1612--1632. PMID:21548867
5. Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Endocrinology. 2001;142(12):5182--9. PMID:11713213
6. European Food Safety Authority (EFSA). Scientific Opinion on the substantiation of health claims related to EPA, DHA, and maintenance of normal cardiac function. EFSA Journal. 2010;8(10):1796. doi:10.2903/j.efsa.2010.1796
7. Vimaleswaran KS, et al. Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomisation analysis of multiple cohorts. PLOS Medicine. 2013;10(2):e1001383. doi:10.1371/journal.pmed.1001383